Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. News
RAPT Therapeutics, Inc. Quantitative Score
About RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
RAPT Therapeutics, Inc. Financials
Table Compare
Compare RAPT metrics with: | |||
|---|---|---|---|
Earnings & Growth | RAPT | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | RAPT | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | RAPT | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | RAPT | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
RAPT Therapeutics, Inc. Income
RAPT Therapeutics, Inc. Balance Sheet
RAPT Therapeutics, Inc. Cash Flow
RAPT Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
RAPT Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Brian Russell Wong M.D., Ph.D. | Chief Executive Officer, President & Director |
| Mr. Rodney K. B. Young | Chief Financial Officer, Principal Accounting Officer & Secretary |
| Dr. William Ho M.D., Ph.D. | Chief Medical Officer |
| Dr. Dirk G. Brockstedt Ph.D. | Chief Scientific Officer |
| Dr. Nipun Davar MBA, Ph.D. | Senior Vice President of Technical Operations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Brian Russell Wong M.D., Ph.D. | Chief Executive Officer, President & Director | 1972 | 1.05M | |
| Mr. Rodney K. B. Young | Chief Financial Officer, Principal Accounting Officer & Secretary | Male | 1963 | 716K |
| Dr. William Ho M.D., Ph.D. | Chief Medical Officer | 1966 | 709.58K | |
| Dr. Dirk G. Brockstedt Ph.D. | Chief Scientific Officer | 1969 | 490.25K | |
| Dr. Nipun Davar MBA, Ph.D. | Senior Vice President of Technical Operations | 1968 | -- |
RAPT Therapeutics, Inc. Insider Trades
| Date | 21 Jun |
| Name | Dombkowski Ashley L. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25000 |
| Date | 21 Jun |
| Name | Dombkowski Ashley L. |
| Role | |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 21 Jun |
| Name | Braunstein Scott |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25000 |
| Date | 21 Jun |
| Name | Braunstein Scott |
| Role | |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 20 Jun |
| Name | HO WILLIAM |
| Role | CHIEF MEDICAL OFFICER |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 75000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 21 Jun | Dombkowski Ashley L. | Director | Acquired | A-Award | 25000 |
| 21 Jun | Dombkowski Ashley L. | Disposed | 0 | ||
| 21 Jun | Braunstein Scott | Director | Acquired | A-Award | 25000 |
| 21 Jun | Braunstein Scott | Disposed | 0 | ||
| 20 Jun | HO WILLIAM | CHIEF MEDICAL OFFICER | Acquired | A-Award | 75000 |